Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Lypressin acetate: Reliable Assay Workflows
2026-09-01
This scenario-based guide explains how Lypressin acetate, SKU N2888, can improve the interpretability of GPCR-linked viability, proliferation, cytotoxicity, and vasopressor experiments. It addresses peptide handling, receptor-context controls, potency normalization, cross-domain antiviral interpretation, and practical supplier selection.
-
Capsazepine for TRPV1 Ion Channel Antagonism
2026-08-31
Capsazepine provides a practical pharmacological switch for separating TRPV1-driven nociception from broader neuronal and cancer-cell responses. This workflow-focused guide covers assay setup, concentration selection, calcium imaging, pain-model interpretation, apoptosis studies, and troubleshooting of solubility and off-target effects.
-
PRMT5, Splicing, and Metabolism in MYCN Neuroblastoma
2026-08-31
The reference study identifies a mechanistic link between PRMT5-dependent spliceosomal control, epitranscriptomic regulation, and glutamine metabolism in MYCN-amplified neuroblastoma. Its integrated pharmacological, transcriptomic, isotope-tracing, molecular, and mouse-model analyses show that altered RNA processing can reduce GLS protein abundance and expose a metabolic vulnerability relevant to cancer metabolism research.
-
7ACC2: Monocarboxylate Transporter 1 Inhibitor
2026-08-30
7ACC2 is a carboxycoumarin monocarboxylate transporter 1 inhibitor that blocks MCT1-associated lactate uptake at a reported IC50 of approximately 10 nM in SiHa cells. Its reported effects on mitochondrial pyruvate transport and tumor radiosensitization make it a useful research probe for cancer metabolism research, but the available evidence does not establish clinical efficacy.
-
Lypressin Acetate: Workflows for GPCR Research
2026-08-29
Lypressin acetate is a lysine-containing vasopressin analog for connecting V1a, V1b, and V2 receptor biology with antidiuretic, vasopressor, and emerging antiviral assays. This workflow-centered guide covers assay setup, quantitative activity interpretation, stability controls, and the limitations of extending receptor pharmacology into SARS-CoV-2 RdRp research.
-
PR-619 for DUB Pathway Assays
2026-08-28
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for separating DUB-driven protein accumulation from direct proteasome blockade. This workflow-focused guide covers dose design, autophagy and ubiquitination assays, cancer biology research, neurodegenerative disease models, and practical troubleshooting.
-
CB-839 and the Splicing–Glutamine Axis in Neuroblastoma
2026-08-28
PRMT5-dependent splicing can expose a glutamine-metabolic weakness in MYCN-amplified neuroblastoma. This article explains how CB-839 (Telaglenastat), a selective GLS1 inhibitor, can serve as a pharmacologic probe for testing that vulnerability while improving translational study design.
-
Viral RIPK3 Degradation and Inflammation
2026-08-27
Liu et al. identified a family of orthopoxvirus proteins, termed viral inducers of RIPK3 degradation, that use host SCF machinery to promote RIPK3 ubiquitination and proteasomal loss. The study connects this immune-evasion mechanism to necroptosis suppression, viral replication, inflammation, and disease severity in mouse infection models.
-
BACE Inhibition, Aβ, and Synaptic Transmission
2026-08-27
Satir et al. tested whether partial β-secretase inhibition could reduce amyloid beta secretion without disrupting neuronal function. Using primary rat cortical cultures and optical electrophysiology, they found that Aβ reduction below 50% did not impair synaptic transmission, whereas stronger inhibition reduced both Aβ secretion and synaptic activity.
-
BCA Protein Assay Kit for Colitis Research
2026-08-26
Discover how the BCA Protein Assay Kit supports rigorous bicinchoninic acid protein quantification in DSS-colitis research. This guide connects matrix-aware protein concentration measurement with barrier biology, immunoassays, and microbiome–metabolome interpretation.
-
Molidustat (BAY85-3934) in Cell Assays
2026-08-26
A scenario-based guide to using Molidustat (BAY85-3934), SKU B5861, in hypoxia, viability, proliferation, and cytotoxicity workflows. It connects HIF-PH biology with formulation control, assay interpretation, and practical product-selection decisions.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-25
A 2026 FASEB Journal study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, altered cell-cycle and DNA-damage markers, and suppressed orthotopic tumor growth while producing strong bladder-localized expression with limited systemic distribution in mice.
-
Mestranol and Reversible Lysosomal Stress in Microglia
2026-08-25
A 2026 Aquatic Toxicology study identifies mestranol as an inducer of a reversible lysosomal storage–like state in zebrafish microglia. The work separates preserved phagocytic uptake from impaired intracellular digestion and provides a live model for studying environmental estrogen–associated neuroimmunotoxicity.
-
Firefly Luciferase mRNA as a Delivery Benchmark
2026-08-24
Firefly Luciferase mRNA can do more than report gene expression: it can reveal how capping, nucleotide modification, poly(A) architecture, and delivery determine functional protein output. This article connects assay design with mechanistic lessons from emerging non-LNP mRNA delivery research.
-
CAMLs in Blood: Phenotypes and Clinical Utility
2026-08-24
The reference study presents circulating cancer-associated macrophage-like cells (CAMLs) as phagocytic polyploid giant cancer cells with measurable links to progression and disease spread across multiple solid tumors. Its prospective, multi-institutional design and biological phenotyping suggest that CAMLs may provide a blood-based window into metastatic niche formation, although their prognostic and mechanistic roles require further validation.